SAFER: sub-hypergraph attention-based neural network for predicting effective responses to dose combinations.

Journal: BMC bioinformatics
PMID:

Abstract

BACKGROUND: The potential benefits of drug combination synergy in cancer medicine are significant, yet the risks must be carefully managed due to the possibility of increased toxicity. Although artificial intelligence applications have demonstrated notable success in predicting drug combination synergy, several key challenges persist: (1) Existing models often predict average synergy values across a restricted range of testing dosages, neglecting crucial dose amounts and the mechanisms of action of the drugs involved. (2) Many graph-based models rely on static protein-protein interactions, failing to adapt to dynamic and higher-order relationships. These limitations constrain the applicability of current methods.

Authors

  • Yi-Ching Tang
  • Rongbin Li
    School of Biomedical Informatics, University of Texas Health Science Center at Houston; Yale University; Melax Technologies, Houston.
  • Jing Tang
    Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
  • W Jim Zheng
    McWilliams School of Biomedical Informatics, University of Texas Health Science at Houston, Houston, TX, USA.
  • Xiaoqian Jiang
    School of Biomedical Informatics, University of Texas Health, Science Center at Houston, Houston, TX, USA.